Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC.PIRS · Entity 4452 | Chief Financial Officer | February 26, 2019 | February 28, 2019 |
| Prime Medicine, Inc.PRME · Entity 5281 | Director · Chief Executive Officer | February 26, 2026 | February 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PALVELLA THERAPEUTICS, INC.
Report date February 26, 2019 · Filed February 28, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.09 · Expires 2029-02-26 | Direct | 162,500 |
Reported balance
After 2019-02-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-02-26 · Grant · Acquired 162,500 · Balance 162,500 F1: The option vests as to 25% of the option shares on February 26, 2020 and vests as to an additional 6.25% of the option shares at the end of each successive three-month period thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as to 25% of the option shares on February 26, 2020 and vests as to an additional 6.25% of the option shares at the end of each successive three-month period thereafter.
Prime Medicine, Inc.
Report date February 26, 2026 · Filed February 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.38 · Expires 2036-02-26 | Direct | 1,300,000 |
Reported balance
After 2026-02-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-26 · Grant · Acquired 1,300,000 · Balance 1,300,000 F1: 1/48th of the shares underlying this option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of February 26, 2026, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the shares underlying this option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of February 26, 2026, subject to the Reporting Person's continued service on each such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Foghorn Therapeutics Inc.
Report date January 16, 2024 · Filed January 17, 2024
Section 16 reporting ended · disclosed 2024-01-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 53,784 |
Reported balance
Holding disclosure · report date 2024-01-16 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 53,784 |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.72 · Expires 2029-09-16 | Direct | 257,513 |
Reported balance
Holding disclosure · report date 2024-01-16 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 257,513 F1: The option vested as to 25% of the underlying shares of common stock on September 17, 2020, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.77 · Expires 2030-08-17 | Direct | 91,891 |
Reported balance
Holding disclosure · report date 2024-01-16 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 91,891 F2: The option vested as to 25% of the underlying shares of common stock on August 18, 2021, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.63 · Expires 2031-01-27 | Direct | 120,000 |
Reported balance
Holding disclosure · report date 2024-01-16 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 120,000 F3: The option vested as to 25% of the underlying shares of common stock on January 28, 2022, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.87 · Expires 2032-01-25 | Direct | 135,000 |
Reported balance
Holding disclosure · report date 2024-01-16 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 135,000 F4: The option vested as to 25% of the underlying shares of common stock on January 26, 2023, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.38 · Expires 2033-01-25 | Direct | 90,000 |
Reported balance
Holding disclosure · report date 2024-01-16 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 90,000 F5: The option vests as to 25% of the underlying shares of common stock on January 26, 2024, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vested as to 25% of the underlying shares of common stock on September 17, 2020, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter.
F2: The option vested as to 25% of the underlying shares of common stock on August 18, 2021, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter.
F3: The option vested as to 25% of the underlying shares of common stock on January 28, 2022, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter.
F4: The option vested as to 25% of the underlying shares of common stock on January 26, 2023, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter.
F5: The option vests as to 25% of the underlying shares of common stock on January 26, 2024, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 26, 2026 Filed Feb 27, 2026 21:52 UTC | Prime Medicine, Inc. PRME · Entity 5281 | GrantStock Option (right to buy) · Derivative | 1,300,000 | $0.00 Strike: $4.38 | $0.00 |
DisclosureSEC source: 0001628280-26-012893 · wk-form4_1772229156.xml · derivative · entry 1 Reine Allan · CIK 0001714023 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,300,000 Underlying: Common Stock · 1,300,000 shares Expires 2036-02-26 F1 · derivative.exercise_date: 1/48th of the shares underlying this option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of February 26, 2026, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| August 01, 2025 Filed Aug 6, 2025 00:42 UTC | Prime Medicine, Inc. PRME · Entity 5281 | GrantStock Option (right to buy) · Derivative | 850,000 | Not disclosed Strike: $4.04 | Not disclosed |
DisclosureSEC source: 0001894562-25-000043 · wk-form4_1754440956.xml · derivative · entry 2 Reine Allan · CIK 0001714023 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 850,000 Underlying: Common Stock · 850,000 shares Expires 2034-01-17 F1 · kind: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| August 01, 2025 Filed Aug 6, 2025 00:42 UTC | Prime Medicine, Inc. PRME · Entity 5281 | Disposition to issuerStock Option (right to buy) · Derivative | 850,000 | Not disclosed Strike: $6.80 | Not disclosed |
DisclosureSEC source: 0001894562-25-000043 · wk-form4_1754440956.xml · derivative · entry 1 Reine Allan · CIK 0001714023 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 850,000 shares Expires 2034-01-17 F1 · kind: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| May 21, 2025 Filed May 22, 2025 20:18 UTC | Prime Medicine, Inc. PRME · Entity 5281 | PurchaseCommon Stock | 125,000 | $1.18 | $147,150.00 |
DisclosureSEC source: 0001894562-25-000026 · wk-form4_1747945107.xml · nonDerivative · entry 1 Reine Allan · CIK 0001714023 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.13 to $1.20, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer or the staff of the Securities and Exchange Commission, upon request, information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| May 19, 2025 Filed May 19, 2025 23:44 UTC | Prime Medicine, Inc. PRME · Entity 5281 | GrantStock Option (right to buy) · Derivative | 2,000,000 | $0.00 Strike: $1.34 | $0.00 |
DisclosureSEC source: 0001894562-25-000023 · wk-form4_1747698248.xml · derivative · entry 1 Reine Allan · CIK 0001714023 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,000,000 Underlying: Common Stock · 2,000,000 shares Expires not disclosed F1 · derivative.exercise_date: 25% of the shares underlying this option shall vest and become exercisable on May 19, 2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. F1 · derivative.expiration_date: 25% of the shares underlying this option shall vest and become exercisable on May 19, 2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| May 08, 2025 Filed May 12, 2025 20:50 UTC | Prime Medicine, Inc. PRME · Entity 5281 | GrantStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $6.80 | $0.00 |
DisclosureSEC source: 0001894562-25-000020 · wk-form4_1747083048.xml · derivative · entry 1 Reine Allan · CIK 0001714023 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 850,000 Underlying: Common Stock · 75,000 shares Expires 2034-01-17 F1 · derivative.exercise_date: Represents an option initially granted to the Reporting Person on January 17, 2024, a portion of which shares underlying this option shall vest upon the achievement of certain performance milestones. On May 8, 2025, the board of directors of the Issuer determined that one of the performance milestone conditions was achieved, resulting in the vesting of 75,000 shares. Read SEC document |
| February 27, 2025 Filed Mar 4, 2025 01:11 UTC | Prime Medicine, Inc. PRME · Entity 5281 | GrantStock Option (right to buy) · Derivative | 275,000 | $0.00 Strike: $2.42 | $0.00 |
DisclosureSEC source: 0001894562-25-000002 · wk-form4_1741050667.xml · derivative · entry 1 Reine Allan · CIK 0001714023 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2035-02-27 F1 · derivative.exercise_date: 1/48th of the shares underlying this option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of February 27, 2025, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| December 05, 2024 Filed Dec 9, 2024 23:22 UTC | Prime Medicine, Inc. PRME · Entity 5281 | GrantStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $6.80 | $0.00 |
DisclosureSEC source: 0001894562-24-000047 · wk-form4_1733786555.xml · derivative · entry 1 Reine Allan · CIK 0001714023 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 775,000 Underlying: Common Stock · 75,000 shares Expires 2034-01-17 F1 · derivative.exercise_date: Represents an option initially granted to the Reporting Person on January 17, 2024, a portion of which shares underlying this option shall vest upon the achievement of certain performance milestones. On December 5, 2024, the board of directors of the Issuer determined that one of the performance milestone conditions was achieved, resulting in the vesting of 75,000 shares. Read SEC document |
| May 17, 2024 Filed May 21, 2024 20:11 UTC | Prime Medicine, Inc. PRME · Entity 5281 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $6.80 | $0.00 |
DisclosureSEC source: 0001894562-24-000024 · wk-form4_1716322282.xml · derivative · entry 1 Reine Allan · CIK 0001714023 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2034-01-17 F1 · derivative.exercise_date: Represents an option initially granted to the Reporting Person on January 17, 2024, a portion of which shares underlying this option shall vest upon the achievement of certain performance milestones. On May 17, 2024, the board of directors of the Issuer determined that one of the performance milestone conditions was achieved, resulting in the vesting of 100,000 shares. Read SEC document |
| January 17, 2024 Filed Jan 19, 2024 21:19 UTC | Prime Medicine, Inc. PRME · Entity 5281 | GrantStock Option (right to buy) · Derivative | 600,000 | $0.00 Strike: $6.80 | $0.00 |
DisclosureSEC source: 0001894562-24-000004 · wk-form4_1705699169.xml · derivative · entry 1 Reine Allan · CIK 0001714023 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Stock · 600,000 shares Expires 2034-01-17 F1 · derivative.exercise_date: 25% of the shares underlying this option shall vest and become exercisable on January 17, 2025, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| January 26, 2023 Filed Jan 30, 2023 17:02 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | GrantStock Option (right to buy) · Derivative | 90,000 | $0.00 Strike: $8.38 | $0.00 |
DisclosureSEC source: 0001562180-23-000722 · primarydocument.xml · derivative · entry 1 Reine Allan · CIK 0001714023 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2033-01-25 F1 · derivative.exercise_date: The option vests as to 25% of the underlying shares of common stock on January 26, 2024, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter. Read SEC document |
| January 26, 2022 Filed Jan 28, 2022 16:26 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | GrantStock Option (right to buy) · Derivative | 135,000 | $0.00 Strike: $14.87 | $0.00 |
DisclosureSEC source: 0001562180-22-000748 · primarydocument.xml · derivative · entry 1 Reine Allan · CIK 0001714023 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,000 Underlying: Common Stock · 135,000 shares Expires 2032-01-25 F1 · derivative.exercise_date: The option vested as to 25% of the underlying shares of common stock on January 26, 2023, the first anniversary of the of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each calendar quarter following such first anniversary until the option is fully vested. Read SEC document |
| August 09, 2021 Filed Aug 11, 2021 16:14 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | Exercise / conversionStock Options (Right to buy) · Derivative | 26,892 | $0.00 Strike: $3.72 | $0.00 |
DisclosureSEC source: 0001562180-21-005284 · primarydocument.xml · derivative · entry 2 Reine Allan · CIK 0001714023 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 257,512 Underlying: Common Stock · 26,892 shares Expires 2029-09-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vested as to 25% of the underlying shares of common stock on September 16, 2020, the first anniversary of the of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each calendar quarter following such first anniversary until the option is fully vested. Read SEC document |
| August 09, 2021 Filed Aug 11, 2021 16:14 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | Exercise / conversionCommon Stock | 26,892 | $3.72 | $100,038.24 |
DisclosureSEC source: 0001562180-21-005284 · primarydocument.xml · nonDerivative · entry 1 Reine Allan · CIK 0001714023 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,784 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 28, 2021 Filed Feb 1, 2021 21:26 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | GrantStock Option (Right to Buy) · Derivative | 120,000 | $0.00 Strike: $16.63 | $0.00 |
DisclosureSEC source: 0000899243-21-003967 · doc4.xml · derivative · entry 1 Reine Allan · CIK 0001714023 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2031-01-27 F1 · derivative.exercise_date: The options will vest as to 25% of the underlying shares of common stock on January 28, 2022, the first anniversary of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each calendar quarter following such first anniversary until the option is fully vested. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 22:24 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | GrantStock Options (Right to Buy) · Derivative | 162,500 | $0.00 Strike: $3.09 | $0.00 |
DisclosureSEC source: 0001562180-19-001487 · primarydocument.xml · derivative · entry 1 Reine Allan · CIK 0001714023 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,500 Underlying: Common Stock · 162,500 shares Expires 2029-02-26 F1 · derivative.exercise_date: The option vests as to 25% of the option shares on February 26, 2020 and vests as to an additional 6.25% of the option shares at the end of each successive three-month period thereafter. Read SEC document |
| February 20, 2018 Filed Feb 27, 2018 00:15 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | GrantStock Options (Right to buy) · Derivative | 50,000 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001562180-18-001252 · primarydocument.xml · derivative · entry 2 Reine Allan · CIK 0001714023 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-08-08 F2 · derivative.exercise_date: On August 9, 2017, the reporting person was granted an option to purchase up to a maximum of 50,000 shares of common stock of which 50,000 shares were earned based on the reporting person's achievement of his 2017 personal goals as certified by the Compensation Committee of the Board of Directors on February 20, 2018. The earned shares vest as to 25% on February 20, 2019 and the remainder vests as to an additional 6.25% quarterly thereafter beginning on the last day of the next calendar quarter. Read SEC document |
| February 20, 2018 Filed Feb 27, 2018 00:15 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | GrantStock Options (Right to buy) · Derivative | 53,833 | $0.00 Strike: $8.56 | $0.00 |
DisclosureSEC source: 0001562180-18-001252 · primarydocument.xml · derivative · entry 1 Reine Allan · CIK 0001714023 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,833 Underlying: Common Stock · 53,833 shares Expires 2028-02-20 F1 · derivative.exercise_date: The option vests as to 25% of the option shares on January 1, 2019 and vests as to an additional 6.25% of the option shares at the end of each successive three-month period thereafter. Read SEC document |
| August 17, 2017 Filed Aug 17, 2017 23:19 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | PurchaseCommon Stock | 20,000 | $4.89 | $97,800.00 |
DisclosureSEC source: 0000899243-17-020635 · doc4.xml · nonDerivative · entry 2 Reine Allan · CIK 0001714023 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Read SEC document |
| August 16, 2017 Filed Aug 17, 2017 23:19 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | PurchaseCommon Stock | 45,000 | $4.79 | $215,550.00 |
DisclosureSEC source: 0000899243-17-020635 · doc4.xml · nonDerivative · entry 1 Reine Allan · CIK 0001714023 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.69 to $4.90, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges sent forth in this footnote. Read SEC document |
| August 09, 2017 Filed Aug 12, 2017 01:20 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | GrantCommon Stock · Derivative | 450,000 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0000899243-17-020179 · doc4.xml · derivative · entry 1 Reine Allan · CIK 0001714023 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 450,000 shares Expires 2027-08-09 F1 · derivative.exercise_date: The option vests as to 25% of the option shares on August 9, 2018 and vests as to an additional 6.25% of the option shares at the end of each successive three-month period thereafter until August 9, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.